9 articles
German drugmaker Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion to enhance its gene silencing capabilities. The all-cash deal values shares at $20 each and is scheduled to close in
Merck KGaA has acquired PostEra’s two oral fertility molecule programs in a deal worth mid-double-digit millions. This move capitalizes on PostEra's recent strategic shift toward developing drug candi
Merck KGaA has entered a definitive agreement to acquire Bio-Techne Corp for $73 per share in cash, totaling approximately $11.3 billion. The transaction offers a 36% premium over Bio-Techne's recent
Merck KGaA has agreed to acquire Bio-Techne Corp for $11.3 billion to expand its life-science research capabilities. The deal includes research reagents, proteins, and antibodies, funded via cash and
Merck KGaA upgraded its 2026 earnings and sales guidance driven by strong momentum in Life Science and Healthcare segments despite currency headwinds. The company cited solid demand across its portfol
Merck KGaA reported an earnings decline attributed to negative currency impacts, projecting sales will only match 2025 levels by 2026 at best.
Merck KGaA partners with ChemLex in Singapore to enhance chemical R&D capabilities through automated synthesis, reaction optimization, and high-throughput experimentation.
Merck KGaA launched an HPC platform in partnership with Lenovo and Equinix to enhance research across all company sectors. This infrastructure aims to accelerate innovation within the company's divers
Merck KGaA reported Q3 earnings that beat estimates while tightening guidance, noting organic growth offset negative currency effects.
ChemBrief